At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 138 enrolled
Drug / intervention
ALY688 0.1% +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2a, Randomized, Double-Masked, Vehicle-Controlled Study Evaluating the Safety and Exploratory Activity of Two Concentrations of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease
In Brief
A Phase 2 clinical trial evaluating ALY688 0.1%, ALY688 0.4%, and 1 other intervention for Dry Eye Disease. Completed, enrolled 138 participants across 1 site.
Detailed Summary
Clinical Trial Evaluating the Safety and Tolerability of ALY688 in Subjects with Dry Eye Disease
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartDec 2019
First PostedDec 2019
Primary CompletionSep 2020
TodayJul 2026
First PostedDec 17, 2019
Enrollment StartDec 16, 2019
Primary CompletionSep 15, 2020
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 6.5 years ago
Interventions
ALY688 0.1%drug
ALY688 0.1% Ophthalmic Solution
ALY688 0.4%drug
ALY688 0.4% Ophthalmic Solution
Vehicledrug
Vehicle Ophthalmic Solution